Glyclaside (diamicron): Effects on metabolism and hemovascular disorders in type II diabetes mellitus (Review of the proceedings of an International Symposium, Istanbul, September, 9, 1993)

Abstract

If in the 70s and in the beginning of the 80s the only second-generation sulfonylurea drug (eguglucon, daonil, mannilil) dominated the treatment of type II diabetes patients, in recent decades, the arsenal of doctors has been replenished with a number of effective second-generation drugs with differences in clinical properties.

One of these drugs is gliclazide (diamicron), well known to domestic endocrinologists. The drug was released by Servier in the late 70s. A significant structural difference between gliclazide and other sulfonylurea preparations is the presence of a heterocyclic nitrogen-containing ring (azabicyclo-octyl ring), which plays an important role in the hemorheological properties of the drug. The accumulated experience in the use of diabetes in different countries was the subject of discussion at a special symposium held as part of the 29th annual conference of the European Association for the Study of Diabetes.

Of particular interest were the reports comparing the effectiveness of various sulfonamides, the incidence of secondary resistance and complications in their use.